Prognostic Value of C-Reactive Protein to Lymphocyte Ratio (CLR) in Emergency Department Patients with SARS-CoV-2 Infection
| Autor: | Pierrick Le Borgne, Lise Bérard, Ndenga Tonduangu, Pascal Bilbault, Karine Alamé, François Lefebvre, Sepsis) (Clr), Stéphane Gennai, C.E. Lavoignet, Lauriane Cipolat, Yannick Gottwalles, Laure Abensur Vuillaume |
|---|---|
| Přispěvatelé: | Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Université de Lorraine (UL), CHU Strasbourg, Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier de Haguenau, CH Colmar, Centre Hospitalier Universitaire de Reims (CHU Reims) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Multivariate analysis Coronavirus disease 2019 (COVID-19) CLR Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Lymphocyte Medicine (miscellaneous) severity Article 03 medical and health sciences 0302 clinical medicine [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases COVID-19 mortality Internal medicine Medicine 030304 developmental biology [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases 0303 health sciences biology business.industry C-reactive protein Retrospective cohort study Emergency department 3. Good health medicine.anatomical_structure [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology 030220 oncology & carcinogenesis Cohort biology.protein business |
| Zdroj: | Journal of Personalized Medicine, Vol 11, Iss 1274, p 1274 (2021) Journal of Personalized Medicine Journal of Personalized Medicine, MDPI, 2021, 11 (12), pp.1274. ⟨10.3390/jpm11121274⟩ Journal of Personalized Medicine; Volume 11; Issue 12; Pages: 1274 |
| ISSN: | 2075-4426 |
| DOI: | 10.3390/jpm11121274⟩ |
| Popis: | (1) Introduction: According to recent studies, the ratio of C-reactive-protein to lymphocyte is more sensitive and specific than other biomarkers associated to systemic inflammatory processes. This study aimed to determine the prognostic value of CLR on COVID-19 severity and mortality at emergency department (ED) admission. (2) Methods: Between 1 March and 30 April 2020, we carried out a multicenter and retrospective study in six major hospitals of northeast France. The cohort was composed of patients hospitalized for a confirmed diagnosis of moderate to severe COVID-19. (3) Results: A total of 1,035 patients were included in this study. Factors associated with infection severity were the CLR (OR: 1.001, CI 95%: (1.000–1.002), p = 0.012), and the lymphocyte level (OR: 1.951, CI 95%: (1.024–3.717), p = 0.042). In multivariate analysis, the only biochemical factor significantly associated with mortality was lymphocyte rate (OR: 2.308, CI 95%: (1.286–4.141), p = 0.005). The best threshold of CLR to predict the severity of infection was 78.3 (sensitivity 79%; specificity 47%), and to predict mortality, was 159.5 (sensitivity 48%; specificity 70%). (4) Conclusion: The CLR at admission to the ED could be a helpful prognostic biomarker in the early screening and prediction of the severity and mortality associated with SARS-CoV-2 infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|